Signal: Absci and AstraZeneca sign deal on AI-powered cancer antibody drug
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.